论文部分内容阅读
目的:探讨常规分割调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效。方法:选择2011年10月-2013年10月门诊和住院治疗的高龄食管癌患者53例。根据治疗模式不同,分为同步组和对照组,同步组采用调强放射治疗同步替吉奥治疗,对照组采用单纯调强放射治疗。结果:同步组较对照组的副反应略高,但差异无统计学意义(P>0.05);同步组和对照组患者总有效率分别达到84.00%和57.14%,差异有统计学意义(P=0.033);同步组和对照组患者12个月随访期内的中位无进展生存期分别为10.84个月和9.36个月,差异有统计学意义(P=0.044),同步组和对照组患者的1年生存率分别为88.0%和85.7%,差异无统计学意义(P=0.75)。结论:调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效肯定。
Objective: To investigate the efficacy of conventional split-intensity-modulated radiation therapy in the treatment of elderly patients with esophageal cancer. Methods: From October 2011 to October 2013, 53 outpatients and hospitalized elderly patients with esophageal cancer were selected. According to the different treatment modes, divided into the synchronization group and the control group, the synchronization group using intensity-modulated radiation therapy for treatment of Gioti, the control group with a simple intensity-modulated radiation therapy. Results: The side effects of the synchronous group were slightly higher than those of the control group, but the difference was not statistically significant (P> 0.05). The total effective rate was 84.00% and 57.14% respectively in the synchronous group and the control group, with significant difference (P = 0.033). The median progression-free survival rates of patients in the control group and the control group at 12 months follow-up were 10.84 months and 9.36 months, respectively, with significant difference (P = 0.044). The patients in the control group and the control group The 1-year survival rates were 88.0% and 85.7%, respectively, with no significant difference (P = 0.75). Conclusions: IMRT is a safe and effective treatment for elderly patients with esophageal cancer.